98%
921
2 minutes
20
Objective: Tight junction proteins have recently been reported to be useful for distinguishing between neoplastic and non-neoplastic tissues. In this study, we evaluated the expression and localization of tight junction transmembrane proteins in human cervical adenocarcinoma and adenocarcinoma in situ (AIS), and we determined whether their expression patterns could distinguish cervical adenocarcinoma from non-neoplastic cervical glands.
Methods: Fifty-five patients with cervical adenocarcinoma or AIS were included in this study. Surgical specimens were immunohistochemically stained for claudin (CLDN) -1, -4, -7, occludin, and JAM-A.
Results: Significantly higher expression levels of CLDNs and JAM-A were found in cervical AIS and adenocarcinoma than in non-neoplastic glands. In cervical AIS and adenocarcinoma, localization of CLDN1 and JAM-A was extended throughout the whole cell membranes, whereas they were predominantly expressed at the most apical cell-cell junction in non-neoplastic glands. ROC curve analysis revealed that immunoreactivities of CLDN-1 or JAM-A successfully distinguished neoplasms from non-neoplastic cervical glands with high specificity (CLDN-1, 79.1%; JAM-A, 79.1%) and high sensitivity (CLDN-1, 84.1%; JAM-A, 95.5%).
Conclusions: As expected, there were immunohistochemical differences between cervical adenocarcinoma and non-neoplastic cervical glands by using antibodies against tight junction transmembrane proteins. These results suggest that CLDN-1 and JAM-A are potential biomarkers for cervical adenocarcinoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.14670/HH-11-729 | DOI Listing |
Biochem Biophys Rep
June 2025
The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong Province, China.
Background: SLC16A3, a highly expressed H + -coupled symporter, facilitates lactate transport via monocarboxylate transporters (MCTs), contributing to acidosis. Although SLC16A3 has been implicated in tumor development, its role in tumor immunity remains unclear.
Methods: A pan-cancer analysis was conducted using datasets from The Cancer Genome Atlas, Cancer Cell Line Encyclopedia, and Genotype-Tissue Expression projects.
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, Mohammed V Military Teaching Hospital, Rabat, Morocco.
Thyroglossal duct carcinoma is a rare clinical condition, accounting for only 1% of operated cases. It is characterized by ectopic thyroid adenocarcinoma developing within thyroglossal duct cysts (TGDCs). Among these, papillary thyroid carcinoma is the most frequently reported pathological type.
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Radiology, Jinshan Hospital, Fudan University, Shanghai, China.
Purpose: To develop a magnetic resonance imaging (MRI)-based radiomics nomogram to predict lymphovascular space invasion (LVSI) status in patients with early-stage cervical adenocarcinoma (CAC).
Methods: Clinicopathological and MRI data from 310 patients with histopathologically confirmed early-stage CAC were retrospectively analyzed. Patients were divided into training (n = 186) and validation (n = 124) cohorts.
Front Oncol
August 2025
Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
Department of Ultrasound, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China.
This research aimed to investigate the preoperative risk factors for lymph node metastasis (LNM) in medullary thyroid carcinoma (MTC) using clinical, pathological, serological, ultrasound, and radiomics characteristics. Additionally, it aimed to explore the diagnostic precision of ultrasound (US) for MTC and LNM. A retrospective analysis of 111 nodules was eligible from 104 patients from January 1, 2000, to December 28, 2024.
View Article and Find Full Text PDF